Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas
暂无分享,去创建一个
I. Lossos | E. Campo | S. Pileri | A. Ferrando | R. Rabadán | M. Piris | T. Palomero | G. Bhagat | Hossein Khiabanian | O. Bernard | G. Inghirami | X. Bustelo | D. Fiore | Sakellarios Zairis | F. Abate | Mi-Yeon Kim | Javier Robles-Valero | L. Couronné | Christine S Kim | M. Laginestra | S. Quinn | Ana C da Silva-Almeida | J. Robles-Valero | Teresa Palomero | S. A. Quinn
[1] Sarah H. Johnson,et al. Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. , 2016, Blood.
[2] Sven Diederichs,et al. The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non‐coding RNA and synonymous mutations , 2016, EMBO molecular medicine.
[3] Yali Xue,et al. BCFtools/RoH: a hidden Markov model approach for detecting autozygosity from next-generation sequencing data , 2016, Bioinform..
[4] H. Aburatani,et al. Integrated molecular analysis of adult T cell leukemia/lymphoma , 2015, Nature Genetics.
[5] S. Katzav. Vav1: A Dr. Jekyll and Mr. Hyde protein – good for the hematopoietic system, bad for cancer , 2015, Oncotarget.
[6] A. Valencia,et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.
[7] J. Armitage. The aggressive peripheral T‐cell lymphomas: 2015 , 2015, American journal of hematology.
[8] A. Rosenwald,et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. , 2015, Cancer cell.
[9] Chris Wiggins,et al. Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer , 2014, BMC Systems Biology.
[10] G. Montoya,et al. The C-Terminal SH3 Domain Contributes to the Intramolecular Inhibition of Vav Family Proteins , 2014, Science Signaling.
[11] X. Bustelo. Vav family exchange factors: an integrated regulatory and functional view , 2014, Small GTPases.
[12] Min Kyung Sung,et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma , 2014, Nature Genetics.
[13] O. Nureki,et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma , 2014, Nature Genetics.
[14] I. Lossos,et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas , 2014, Nature Genetics.
[15] Raul Rabadan,et al. SAVI: a statistical algorithm for variant frequency identification , 2013, BMC Systems Biology.
[16] B. Nathwani,et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Armitage,et al. The aggressive peripheral T‐cell lymphomas: 2012 update on diagnosis, risk stratification, and management , 2012, American journal of hematology.
[18] M. Oberley,et al. Vav1 in hematologic neoplasms, a mini review. , 2012, American journal of blood research.
[19] Christopher A. Maher,et al. ChimeraScan: a tool for identifying chimeric transcription in sequencing data , 2011, Bioinform..
[20] K. Savage,et al. Peripheral T-cell lymphoma, not otherwise specified. , 2017, Blood.
[21] P. Gaulard,et al. Pathology and biology of peripheral T‐cell lymphomas , 2011, Histopathology.
[22] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[23] John S. Olson,et al. The structure and NO binding properties of the nitrophorin‐like heme‐binding protein from Arabidopsis thaliana gene locus At1g79260.1 , 2010, Proteins.
[24] Michael K. Rosen,et al. Structural and Energetic Mechanisms of Cooperative Autoinhibition and Activation of Vav1 , 2010, Cell.
[25] S. Smerdon,et al. Function of the Nucleotide Exchange Activity of Vav1 in T Cell Development and Activation , 2009, Science Signaling.
[26] X. Bustelo,et al. The Use of Knockout Mice Reveals a Synergistic Role of the Vav1 and Rasgrf2 Gene Deficiencies in Lymphomagenesis and Metastasis , 2009, PloS one.
[27] D. Kioussis,et al. Rac GTPases play critical roles in early T-cell development. , 2009, Blood.
[28] Cui-zhu Zhang,et al. The Calponin Homology Domain of Vav1 Associates with Calmodulin and Is Prerequisite to T Cell Antigen Receptor-induced Calcium Release in Jurkat T Lymphocytes* , 2007, Journal of Biological Chemistry.
[29] Kathleen C. Lee,et al. S100A7 (Psoriasin): a story of mice and men. , 2006, The Journal of investigative dermatology.
[30] Somasekar Seshagiri,et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.
[31] V. Tybulewicz,et al. Vav-family proteins in T-cell signalling. , 2005, Current opinion in immunology.
[32] J. Chernoff,et al. Vav1 Transduces T Cell Receptor Signals to the Activation of the Ras/ERK Pathway via LAT, Sos, and RasGRP1* , 2004, Journal of Biological Chemistry.
[33] H. Müller-Hermelink,et al. Die WHO-Klassifikation maligner Lymphome , 2002, Der Radiologe.
[34] X. Bustelo,et al. Structural Determinants for the Biological Activity of Vav Proteins* , 2002, The Journal of Biological Chemistry.
[35] A. Duncan,et al. Pleiotropic defects in TCR signaling in a Vav‐1‐null Jurkat T‐cell line , 2002, The EMBO journal.
[36] D. Kioussis,et al. Vav1 Transduces T Cell Receptor Signals to the Activation of Phospholipase C-γ1 via Phosphoinositide 3-Kinase-dependent and -independent Pathways , 2002, The Journal of experimental medicine.
[37] L. Chasin,et al. Human Genomic Sequences That Inhibit Splicing , 2000, Molecular and Cellular Biology.
[38] A. Weiss,et al. A Guanine Nucleotide Exchange Factor-independent Function of Vav1 in Transcriptional Activation* , 2000, The Journal of Biological Chemistry.
[39] M. Turner,et al. The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-kappaB pathways. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[40] J. Penninger,et al. Vav Regulates Peptide-specific Apoptosis in Thymocytes , 1998, The Journal of experimental medicine.
[41] F. Alt,et al. Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction , 1998, Current Biology.
[42] K. Tedford,et al. Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor , 1998, Current Biology.
[43] R. Zamoyska,et al. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. , 1997, Immunity.
[44] C. Fizames,et al. Cloning of the genes encoding two murine and human cochlear unconventional type I myosins. , 1997, Genomics.
[45] K. Schuebel,et al. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product , 1997, Nature.
[46] J. Wu,et al. A functional T-cell receptor signaling pathway is required for p95vav activity , 1995, Molecular and cellular biology.
[47] F. Alt,et al. Defective signalling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene , 1995, Nature.
[48] K. Rajewsky,et al. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav , 1995, Nature.
[49] J. Cleveland,et al. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential , 1991, Molecular and cellular biology.
[50] M. Barbacid,et al. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. , 1989, The EMBO journal.
[51] A. J. Lukes. Classification of malignant lymphomas. , 1981, The Western journal of medicine.